The US Bankruptcy Court granted a first order for the extension of the exclusivity periods for PhaseBio Pharmaceuticals, Inc. on March 13, 2023. As per the order, the debtor's exclusivity period to file its plan and to solicit votes on its plan, have been extended by 90 days i.e. up to May 22, 2023 and July 20, 2023, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- PHAS.Q Stock
- News PhaseBio Pharmaceuticals, Inc.
- First Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.